Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Relapse reduction in multiple sclerosis was robust, though lower than in the first Phase III trial, but the drug missed the statistical mark on disability progression.
You may also be interested in...
Third Trial For Teva’s Laquinimod Hinges On SPA From FDA
Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.
German HTA Assessment Knocks Back Gilenya In Europe
IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.